Announced Wed, 8 Jul · 12:51 IST
Suven allots shares on warrant conversion, sets up Singapore subsidiary
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+10.2%1-day move
₹317.50
prior close
₹321.75
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.1+0.9+0.8+10.2+12.3+13.1+9.9+12.5+2.2————
Up moveDown movePending
AI summary
Suven Life Sciences board approved conversion of 1,85,70,133 warrants into equity shares at Rs 134 each to 17 non-promoter allottees, raising Rs 248.84 crore. Paid-up capital rose to Rs 28.26 crore. Board re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years and approved Suven Neurosciences Pte. Ltd., a wholly owned subsidiary in Singapore, with USD 100 million investment focused on neurological disorder treatments.
Likely market impact
Equity dilution from warrant conversion. Singapore WOS signals overseas push into neurological therapeutics with USD 100 million commitment.